Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Cohort B Dissolve200mm

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 1 (2)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT03376646Not ApplicableCompletedPrimary

A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary Small Vessel Disease

NCT01581632Phase 1Completed

Assessment of Coronary Plaque Composition

NCT01642173Phase 1Completed

Assessment of Coronary Plaque Composition Using Optical Coherence Tomography

Showing all 3 trials

Research Network

Common Treatments

  • Cohort B Dissolve200mm1
  • Cohort A Resolute Integrity1
  • Cohort A Dissolve1
  • Lipiscanlipiscan Ivus1
  • Optical Coherence Tomography C7 Xr Dragonfly1

Active Sponsors

  • Mayo Clinic2
  • Core Medical (Beijing) Co., Ltd.1
  • GSK1
  • DK Medical Technology (Suzhou) Co., Ltd.1

Top Investigators

Related Conditions

  • Coronary Atherosclerosis2
  • Endothelial Dysfunction2

Activity Timeline